PREDICTING RESPONSES TO ANDROGEN DEPRIVATION THERAPY

摘要

This document provides methods and materials for identifying prostate cancer patients likely to respond to an androgen deprivation therapy. For example, methods and materials for identifying a prostate cancer patient likely to respond to an androgen deprivation therapy based at least in part on the presence of a genetic variation in a TMRT11 nucleic acid are provided. This document also provides methods and materials for identifying prostate cancer patients likely to survive prostate cancer related death for a short or long period of time. For example, methods and materials for identifying a prostate cancer patient likely to survive prostate cancer related death for a short or long period of time based at least in part on the presence of a genetic variation in a UGT1A3 nucleic acid, a UGT1A7 nucleic acid, and/or a UGT1A10 nucleic acid are provided.